Patents by Inventor George M. Garrity

George M. Garrity has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclic FR-900520 microbial biotransformation agent
    Patent number: 5268281
    Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6968) ATCC No. 55279. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
    Type: Grant
    Filed: September 28, 1992
    Date of Patent: December 7, 1993
    Assignee: Merck & Co., Inc.
    Inventors: George M. Garrity, Magda M. Gagliardi, Shieh-Shung T. Chen
  • Cyclic FR-900520 microbial biotransformation agent
    Patent number: 5268282
    Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6970) ATCC No. 55281. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
    Type: Grant
    Filed: September 28, 1992
    Date of Patent: December 7, 1993
    Assignee: Merck & Co., Inc.
    Inventors: George M. Garrity, Shieh-Shung T. Chen
  • Cyclcic FR-900520 microbial biotransformation agent
    Patent number: 5221625
    Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6963) ATCC No. 55230. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
    Type: Grant
    Filed: January 10, 1992
    Date of Patent: June 22, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Shieh-Shung T. Chen, Raymond F. White, Georgette Dezeny, Brian R. Petuch, George M. Garrity, Byron H. Arison, Amy M. Bernick
  • Immunosuppressant-producing culture
    Patent number: 5202258
    Abstract: Described is a new microorganism, Actinoplanacete sp., (Merck Culture Collection MA 6559) ATCC No. 53771. The microorganism acts as a demethylating agent and can produce the new immunosuppressants, "demethomycin" (L-682,993) a C-31 demethylated analog of L-679,934, and "demethimmunomycin" (L-683,742) a C-31 demethylated analog of L-683,590, under novel fermentation conditions. These macrolide immunosuppressants are useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
    Type: Grant
    Filed: March 9, 1992
    Date of Patent: April 13, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Shieh-Shung T. Chen, Byron H. Arison, George M. Garrity, Edward S. Inamine, Sagrario Mochales, Linda S. Wicker
  • Microorganism for producing C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
    Patent number: 5198358
    Abstract: Described is a process for producing a new immunosuppressant, a C-31 desmethyl, C-19/C-22 cyclic hemiketal biotransformation analog (Compound I) of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces, lavendulae ATCC No. 55209. Also disclosed is the C-31 methylated derivative (Compound II) of Compound I produced by enzymatic methylation using 31-O-desmethylimmunomycin O-methyl transferase, (DIMT), a methyl transferase enzyme. The macrolide immunosuppressants are useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
    Type: Grant
    Filed: August 28, 1991
    Date of Patent: March 30, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Magda M. Gagliardi, Shieh-Shung T. Chen, George M. Garrity
  • Process for producing FK-506
    Patent number: 5194378
    Abstract: Described is a new process for producing the macrolide immunosuppressant, FK-506 under fermentation conditions utilizing the microorganism, Streptomyces sp., (Merck Culture Collection No. MA 6858) ATCC No. 55098. The immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
    Type: Grant
    Filed: October 7, 1991
    Date of Patent: March 16, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Gino M. Salituro, Francis Dumont, George M. Garrity, Leeyuan Huang, E. Tracy T. Jones, Mary N. Omstead, Isabel M. Fernandez, Teresa D. Matas
  • Process for producing FK-506
    Patent number: 5116756
    Abstract: Described is a new process for producing the macrolide immunosuppressant, FK-506 under fermentation conditions utilizing the microorganism, Streptomyces sp., (Merck Culture Collection No. MA 6858) ATCC No. 55098. The immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
    Type: Grant
    Filed: January 28, 1991
    Date of Patent: May 26, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Francis Dumont, George M. Garrity, Isabel M. Fernandez, Teresa D. Matas
  • Antibiotic agent
    Patent number: 5091413
    Abstract: An antibiotic agent produced by the cultivation of Dictyochaeta simplex is described. The compound has broad antifungal activity and antipneumocystis activity.
    Type: Grant
    Filed: February 13, 1990
    Date of Patent: February 25, 1992
    Assignee: Merck & Co., Inc.
    Inventors: George M. Garrity, Sagrario M. Del Val, Mary Nallin, Dennis M. Schmatz, Jack L. Smith, Frank L. VanMiddlesworth, Kenneth E. Wilson, Marcia M. Zweerink
  • Novel HMG-CoA synthase inhibitors
    Patent number: 5064856
    Abstract: Compound of formulae (I) and (II) are HMG-CoA synthase inhibitors and exhibit antifungal activity.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: November 12, 1991
    Assignee: Merck & Co., Inc.
    Inventors: George M. Garrity, Robert Giacobbe, Michael D. Greenspan, Otto D. Hensens, Henry Joshua, Maria T. D. Matas, Isabel Martin, James A. Milligan, Sagrario M. del Val, Walter Rozdilsky, Janet C. Onishi, Jerrold M. Liesch
  • Antifungal fermentation products and compositions thereof
    Patent number: 5019593
    Abstract: A mixture of derivatives of 2-amino-3,4,5,14-tetrahydroxy-6-eicosenoic acid has been isolated from a culture medium after cultivation of microorganisms belonging to the genus Aspergillus. The compounds are useful as antifungal agents.
    Type: Grant
    Filed: July 29, 1987
    Date of Patent: May 28, 1991
    Assignee: Merck & Co., Inc.
    Inventors: George M. Garrity, Maria B. Lopez, Otto D. Hensens, Richard L. Monaghan, Deborah L. Zink
  • Antifungal fermentation product
    Patent number: 5008187
    Abstract: A new antifungal agent which exhibits a moderately broad spectrum of activity towards filamentous fungi and also against Cryptococcus species of the yeast fungi, and which has been isolated from a solid stationary fermentation of an unidentified species of Fusarium is described.
    Type: Grant
    Filed: December 1, 1988
    Date of Patent: April 16, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Louis Chaiet, Sheldon B. Zimmerman, Richard L. Monaghan, George M. Garrity